Abstract
OBJECTIVE: The dopamine re-ceptor 2 (DRD2) binds dopamine in both cen-tral tissues (e.g., basal ganglia, pituitary gland) and peripheral tissues (e.g., adrenal gland, kid-neys, intestine) and mediates dopamine actions in cognition, emotional processing, and prolac-tin-secretion inhibition and stimulation, and in DRD2-/- knockout mice insulin secretion is im-paired. Variants in or around the DRD2 gene have been implicated in major depressive disor-der (MDD), schizophrenia, obesity, and type 2 di-abetes (T2D) but not in comorbid MDD-T2D pa-tients; DRD2 agonists (e.g., bromocriptine) are approved treatments in T2D. This study aimed to detect whether the DRD2 gene plays a role in T2D, MDD, and T2D-MDD comorbidity in Ital-ian families.SUBJECTS AND METHODS: In 212 Italian families with T2D and MDD, we investigated the presence of linkage and linkage disequilibrium of variants in the DRD2 gene with T2D and/or MDD. A test was considered statistically signifi-cant if p was <0.05.RESULTS: We found 3 novel variants (rs6276, rs35608204, and rs1800499) significantly linked to and/or associated with the risk of T2D and 1 novel variant (rs112646785) significantly linked and associated to the comorbidity of T2D and MDD.CONCLUSIONS: This is the first study to link and associate DRD2 variants with the comorbid-ity of T2D and MDD.

This publication has 20 references indexed in Scilit: